Sodium bicarbonate and Opdivo drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sodium bicarbonate (sodium bicarbonate) and Opdivo (nivolumab). Common drug interactions include death among females and malignant neoplasm progression among males.

The phase IV clinical study analyzes what interactions people have when they take Sodium bicarbonate and Opdivo. It is created by eHealthMe based on reports of 73 people who take the same drugs from the FDA, and is updated regularly.

What is Sodium bicarbonate?

Sodium bicarbonate has active ingredients of sodium bicarbonate. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 27,283 Sodium bicarbonate users. Check the latest studies of Sodium bicarbonate.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 25, 2026

73 people who take Sodium bicarbonate and Opdivo together, and have interactions are studied.

Sodium bicarbonate and Opdivo drug interactions.

What are the common drug interactions of Sodium Bicarbonate and Opdivo, by gender? *:

female:

  1. Death
  2. Adverse event
  3. Colitis microscopic (inflammation of colon with diarrhoea and abdominal cramps)
  4. Genital infection fungal
  5. Malignant neoplasm progression (cancer tumour came back)
  6. Oral fungal infection
  7. Reiter's syndrome (a type of reactive arthritis, it happens as a reaction to a bacterial infection)
  8. Stomatitis (inflammation of mucous membrane of mouth)
  9. Abdominal pain
  10. Cough

male:

  1. Malignant neoplasm progression (cancer tumour came back)
  2. Pruritus (severe itching of the skin)
  3. Cholestasis (a condition where bile cannot flow from the liver to the duodenum)
  4. Metastases to central nervous system (cancer spreads to central nervous system)
  5. Blood pressure increased
  6. Dry skin
  7. Rash pruritic (redness with itching)
  8. Adrenal insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids)
  9. Death
  10. Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)

What are the common drug interactions of Sodium Bicarbonate and Opdivo, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function)
  2. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
  3. Lymphatic fistula (a leakage of lymphatic fluid from lymphatic vessel)
  4. Malignant neoplasm progression (cancer tumour came back)

50-59:

  1. Malignant neoplasm progression (cancer tumour came back)
  2. Pruritus (severe itching of the skin)
  3. Renal failure (kidney dysfunction)
  4. Death
  5. Anxiety disorder
  6. Cholangitis (infection of the bile duct)
  7. Electrolyte imbalance
  8. Neuropathy peripheral (surface nerve damage)
  9. Thyroid disorder (thyroid diseases)

60+:

  1. Malignant neoplasm progression (cancer tumour came back)
  2. Diarrhoea
  3. Metastases to central nervous system (cancer spreads to central nervous system)
  4. Adrenal insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids)
  5. Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
  6. Pericardial effusion malignant (cancerous fluid around the heart)
  7. Blood pressure increased
  8. Dry skin
  9. Pruritus (severe itching of the skin)
  10. Pyrexia (fever)

What are the existing conditions these people have? *

  1. Renal Cell Carcinoma (a kidney cancer): 34 people, 46.58%
  2. Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 9 people, 12.33%
  3. Type 2 Diabetes: 8 people, 10.96%
  4. Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 7 people, 9.59%
  5. Pain: 5 people, 6.85%
  6. Metastases To Lung (cancer spreads to lung): 5 people, 6.85%
  7. Malignant Melanoma (skin cancer rises from melancytes): 5 people, 6.85%
  8. High Blood Pressure: 4 people, 5.48%

* Approximation only. Some reports may have incomplete information.

Do you take Sodium bicarbonate and Opdivo?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Sodium bicarbonate and Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Sodium bicarbonate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Sodium bicarbonate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Opdivo and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on sodium bicarbonate and nivolumab (the active ingredients of Sodium bicarbonate and Opdivo, respectively), and Sodium bicarbonate and Opdivo (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: